Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI in Newly Diagnosed Glioblastoma or Gliosarcoma
NCT04817254Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival. Started Dec 2021; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04817254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817254.